Eletriptan Skeletal

Eletriptan, sold under the brand name Relpax and used in the form of eletriptan hydrobromide, is a second generation triptan medication intended for treatment of migraine headaches. It is used as an abortive medication, blocking a migraine attack which is already in progress. Eletriptan is marketed and manufactured by Pfizer Inc.

Approval and availability

Eletriptan was approved by the US Food and Drug Administration (FDA) on December 26, 2002, for the acute treatment of migraine with or without aura in adults. It is available only by prescription in the United States and Canada. It is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. It is available in 20 mg and 40 mg strengths.

Eletriptan was covered by and ; both now expired.

Mechanism of action

Eletriptan is believed to reduce swelling of the blood vessels surrounding the brain. This swelling is associated with the head pain of a migraine attack. Eletriptan blocks the release of substances from nerve endings that cause more pain and other symptoms like nausea, and sensitivity to light and sound. It is thought that these actions contribute to relief of symptoms by eletriptan.

Eletriptan is a serotonin receptor agonist, specifically an agonist of certain 5-HT₁ family receptors. Eletriptan binds with high affinity to the 5-HT _1D,_ _1D,_ _1F/sub>.html"_;"title="5-HT1F.html"_;"title="5-HT1D.html"_;"title="B_,_5-HT1D">_1D,_5-HT1F">_{1F/sub>">5-HT1F.html"_;"title="5-HT1D.html"_;"title="B,}_5-HT1D">_1D,_5-HT1F">_{1F/sub>_receptors._It_has_a_modest_affinity_to_the_ 1F/sub>.html"_;"title="5-HT1F.html"_;"title="5-HT1D.html"_;"title="B,}_5-HT1D">_1D,_5-HT1F">_{1F/sub>">5-HT1F.html"_;"title="5-HT1D.html"_;"title="B,}_5-HT1D">_1D,_5-HT1F">_{1F/sub>_receptors._It_has_a_modest_affinity_to_the_5-HT1A">5-HT[1A,_ 1F/sub>.html"_;"title="5-HT1F.html"_;"title="5-HT1D.html"_;"title="B,}_5-HT1D">_1D,_5-HT1F">_{1F/sub>">5-HT1F.html"_;"title="5-HT1D.html"_;"title="B,}_5-HT1D">_1D,_5-HT1F">_{1F/sub>_receptors._It_has_a_modest_affinity_to_the_5-HT1A">5-HT[1A,_5-HT1E">1E,_ 1F/sub>.html"_;"title="5-HT1F.html"_;"title="5-HT1D.html"_;"title="B,}_5-HT1D">_1D,_5-HT1F">_{1F/sub>">5-HT1F.html"_;"title="5-HT1D.html"_;"title="B,}_5-HT1D">_1D,_5-HT1F">_{1F/sub>_receptors._It_has_a_modest_affinity_to_the_5-HT1A">5-HT[1A,_5-HT1E">1E,_5-HT2B_receptor">2B,_5-HT7.html" ;"title="5-HT2B_receptor.html" ;"title="5-HT1E.html" ;"title="5-HT1A.html" ;"title="5-HT1F">1F/sub>.html" ;"title="5-HT1F.html" ;"title="5-HT1D.html" ;"title="B, 5-HT1D">1D, 5-HT1F">1F/sub>">5-HT1F.html" ;"title="5-HT1D.html" ;"title="B, 5-HT1D">1D, 5-HT1F">1F/sub> receptors. It has a modest affinity to the 5-HT1A">5-HT[1A, 5-HT1E">1E, 5-HT2B receptor">2B, 5-HT7">7/sub> receptors, and little to no affinity at the 5-HT2A, 5-HT[2A, 5-HT2C receptor, 2C, 5-HT3, 3, 5-HT4, 4, 5A, 6/sub> receptors.}

Eletriptan has no significant affinity or pharmacological activity at adrenergic receptor, adrenergic α₁, α₂, or β; dopaminergic D₁ or D₂; muscarinic; or opioid receptors. Eletriptan could be efficiently co-administrated with nitric oxide synthase (NOS's) inhibitors for the treatment of NOS-dependent diseases (US patent US 2007/0254940).

Two theories have been proposed to explain the efficacy of 5-HT₁ receptor agonists in migraine. One theory suggests that activation of 5-HT₁ receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is correlated with the relief of migraine headache. The other hypothesis suggests that activation of 5-HT₁ receptors on sensory nerve endings in the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.

Side effects

Common side effects include hypertension, tachycardia, headache, dizziness, drowsiness and symptoms similar to angina pectoris. Severe allergic reactions are rare.

Contraindications

Eletriptan is contraindicated in patients with various diseases of the heart and circulatory system, such as angina pectoris, severe hypertension, and heart failure, as well as in patients that have had a stroke or heart attack. This is due to the unusual side effect of coronary vasoconstriction due to serotonin 5HT_1B antagonism, which can precipitate a heart attack in those already at risk. It is also contraindicated in severe renal or hepatic impairment due to its extensive liver metabolism through CYP3A4.

Interactions

Strong inhibitors of the liver enzyme CYP3A4, such as erythromycin and ketoconazole, significantly increase blood plasma concentration of eletriptan and should be separated by at least 72 hours. Ergot alkaloids, such as dihydroergotamine, add to the drug's hypertensive effect and should be separated by at least 24 hours.

Additional chemical names

* Merck Index: 3- (2''R'')-1-Methyl-2-pyrrolidinylethyl]-5- -(phenylsulfonyl)ethyl1H-indole
* 5- -(benzenesulfonyl)ethyl3-(1-methylpyrrolidin-2(''R'')-ylmethyl)-1H-indole
* (''R'')-5- -(phenylsulfonyl)ethyl3- 1-methyl-2-pyrrolidinyl)methyl1H-indole

Society and culture

Brand names

It is sold in the United States, Canada, Australia, and the United Kingdom under the brand name Relpax, and in several other countries under the brand name Relert.

References

External links

*
*

{{Portal bar , Medicine

5-HT1D agonists
5-HT1E agonists
5-HT1F agonists
Triptans
Pfizer brands
Pyrrolidines
Benzosulfones